Abstract
Pancreatic cancer is a deadly malignancy with still high mortality and poor survival despite the significant advances in understanding, diagnosis, and access to conventional and novel treatments. Though cytotoxic chemotherapy based on the purine analogue gemcitabine remains the standard approach in adjuvant and palliative setting the need for novel agents aiming at the main pathophysiological abnormalities and molecular pathways involved remains soaring. So far, evidence of clinical benefit, though small, exists only from the addition of the targeted agent erlotinib on the standard gemcitabine chemotherapy. Apart from the popular monoclonal antibodies and small molecules tyrosine kinase inhibitors, other novel compounds being tested in preclinical and clinical studies target mTOR, NF-κB, proteasome and histone deacetylase. These new drugs along with gene therapy and immunotherapy, which are also under clinical evaluation, may alter the unfavorable natural course of this disease. In this review we present the main pathophysiological alterations met in pancreatic cancer and the results of the florid preclinical and clinical research with regards to the targeted therapy associated to these abnormalities.
Similar content being viewed by others
References
Heywood, G., Vezeridis, M. P., & Wanebo, H. J. (1998). Surgical therapy of pancreatic cancer. Frontiers in Bioscience, 3, E175–E180.
Espey, D. K., Wu, X. C., Swan, J., Wiggins, C., Jim, M. A., Ward, E., et al. (2007). Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer, 110, 2119–2152.
Lowenfels, A. B., & Maisonneuve, P. (2004). Epidemiology and prevention of pancreatic cancer. Japanese Journal of Clinical Oncology, 34(5), 238–244.
Hansen, R., Quebbeman, E., Ritch, P., Chitambar, C., & Anderson, T. (1988). Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. American Journal of the Medical Sciences, 295(2), 91–93.
Burris III, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15(6), 2403–2413.
Moskaluk, C. A., Hruban, R. H., & Kern, S. E. (1997). p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Research, 57(11), 2140–2143.
Hruban, R. H., Adsay, N. V., Albores-Saavedra, J., Compton, C., Garrett, E. S., Goodman, S. N., et al. (2001). Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. American Journal of Surgical Pathology, 25(5), 579–586.
Lumadue, J. A., Griffin, C. A., Osman, M., & Hruban, R. H. (1995). Familial pancreatic cancer and the genetics of pancreatic cancer. Surgical Clinics of North America, 75(5), 845–855.
Dang, C. X., Han, Y., Qin, Z. Y., & Wang, Y. J. (2002). Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 1(2), 302–305.
Dergham, S. T., Dugan, M. C., Kucway, R., Du, W., Kamarauskiene, D. S., Vaitkevicius, V. K., et al. (1997). Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. International Journal of Pancreatology, 21(2), 127–143.
Dong, M., Dong, Q., Zhang, H., Zhou, J., Tian, Y., & Dong, Y. (2007). Expression of Gadd45a and p53 proteins in human pancreatic cancer: Potential effects on clinical outcomes. Journal of Surgical Oncology, 95(4), 332–336.
Bloomston, M., Bhardwaj, A., Ellison, E. C., & Frankel, W. L. (2006). Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Digestive Surgery, 23(1–2), 74–79.
Dugan, M. C., Dergham, S. T., Kucway, R., Singh, K., Biernat, L., Du, W., et al. (1997). HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas, 14(3), 229–236.
Schutte, M., Hruban, R. H., Hedrick, L., Cho, K. R., Nadasdy, G. M., Weinstein, C. L., et al. (1996). DPC4 gene in various tumor types. Cancer Research, 56(11), 2527–2530.
Hua, Z., Zhang, Y. C., Hu, X. M., & Jia, Z. G. (2003). Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World Journal of Gastroenterology, 9(12), 2764–2767.
Goggins, M., Schutte, M., Lu, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., et al. (1996). Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Research, 56(23), 5360–5364.
Chadha, K. S., Khoury, T., Yu, J., Black, J. D., Gibbs, J. F., Kuvshinoff, B. W., et al. (2006). Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Annals of Surgical Oncology, 13(7), 933–939.
Lal, G., Liu, G., Schmocker, B., Kaurah, P., Ozcelik, H., Narod, S. A., et al. (2000). Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Research, 60(2), 409–416.
Simon, B., Bartsch, D., Barth, P., Prasnikar, N., Munch, K., Blum, A., et al. (1998). Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Research, 58(8), 1583–1587.
Wang, Z., Banerjee, S., Li, Y., Rahman, K. M., Zhang, Y., & Sarkar, F. H. (2006). Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Research, 66(5), 2778–2784.
Wang, Z., Zhang, Y., Li, Y., Banerjee, S., Liao, J., & Sarkar, F. H. (2006). Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Molecular Cancer Therapeutics, 5(3), 483–493.
Albazaz, R., Verbeke, C. S., Rahman, S. H., & McMahon, M. J. (2005). Cyclooxygenase-2 expression associated with severity of PanIN lesions: A possible link between chronic pancreatitis and pancreatic cancer. Pancreatology, 5(4–5), 361–369.
Juuti, A., Louhimo, J., Nordling, S., Ristimaki, A., & Haglund, C. (2006). Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. Journal of Clinical Pathology, 59(4), 382–386.
Okami, J., Yamamoto, H., Fujiwara, Y., Tsujie, M., Kondo, M., Noura, S., et al. (1999). Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clinical Cancer Research, 5(8), 2018–2024.
Maitra, A., Ashfaq, R., Gunn, C. R., Rahman, A., Yeo, C. J., Sohn, T. A., et al. (2002). Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. American Journal of Clinical Pathology, 118(2), 194–201.
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53(4), 549–554.
Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J., & Bos, J. L. (1988). KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Research, 16(16), 7773–7782.
Hruban, R. H., van Mansfeld, A. D., Offerhaus, G. J., van Weering, D. H., Allison, D. C., Goodman, S. N., et al. (1993). K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American Journal of Pathology, 143(2), 545–554.
van Heek, T., Rader, A. E., Offerhaus, G. J., McCarthy, D. M., Goggins, M., Hruban, R. H., et al. (2002). K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. American Journal of Clinical Pathology, 117(5), 755–765.
Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., et al. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research, 57(9), 1731–1734.
Kawesha, A., Ghaneh, P., Andren-Sandberg, A., Ograed, D., Skar, R., Dawiskiba, S., et al. (2000). K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. International Journal of Cancer, 89(6), 469–474.
Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23(25), 5900–5909.
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., et al. (2007). Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer, 96(8), 1166–1169.
Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., et al. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57(15), 3126–3130.
Huang, L., Goodrow, T. L., Zhang, S. Y., Klein-Szanto, A. J., Chang, H., & Ruggeri, B. A. (1996). Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Research, 56(5), 1137–1141.
Hu, Y. X., Watanabe, H., Ohtsubo, K., Yamaguchi, Y., Ha, A., Okai, T., et al. (1997). Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clinical Cancer Research, 3(9), 1473–1477.
Naka, T., Kobayashi, M., Ashida, K., Toyota, N., Kaneko, T., & Kaibara, N. (1998). Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. International Journal of Oncology, 12(5), 1111–1116.
Barton, C. M., Staddon, S. L., Hughes, C. M., Hall, P. A., O’Sullivan, C., Kloppel, G., et al. (1991). Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. British Journal of Cancer, 64(6), 1076–1082.
Dong, M., Ma, G., Tu, W., Guo, K. J., Tian, Y. L., & Dong, Y. T. (2005). Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World Journal of Gastroenterology, 11(14), 2162–2165.
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74(6), 957–967.
Lowe, S. W. (1995). Cancer therapy and p53. Current Opinion in Oncology, 7(6), 547–553.
Sun, Y. (2006). p53 and its downstream proteins as molecular targets of cancer. Molecular Carcinogenesis, 45(6), 409–415.
Zhan, M., Yu, D., Lang, A., Li, L., & Pollock, R. E. (2001). Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer, 92(6), 1556–1566.
Lang, D., Miknyoczki, S. J., Huang, L., & Ruggeri, B. A. (1998). Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Oncogene, 16(12), 1593–1602.
Nakamori, S., Yashima, K., Murakami, Y., Ishikawa, O., Ohigashi, H., Imaoka, S., et al. (1995). Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Japanese Journal of Cancer Research, 86(2), 174–181.
Dong, M., Nio, Y., Yamasawa, K., Toga, T., Yue, L., & Harada, T. (2003). p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. Journal of Surgical Oncology, 82(2), 111–120.
Gerdes, B., Ramaswamy, A., Ziegler, A., Lang, S. A., Kersting, M., Baumann, R., et al. (2002). p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Annals of Surgery, 235(1), 51–59.
Saif, M. W., Karapanagiotou, L., & Syrigos, K. (2007). Genetic alterations in pancreatic cancer. World Journal of Gastroenterology, 13(33), 4423–4430.
Massague, J., Blain, S. W., & Lo, R. S. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell, 103(2), 295–309.
Miyaki, M., & Kuroki, T. (2003). Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and Biophysical Research Communications, 306(4), 799–804.
Wilentz, R. E., Iacobuzio-Donahue, C. A., Argani, P., McCarthy, D. M., Parsons, J. L., Yeo, C. J., et al. (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Research, 60(7), 2002–2006.
Howe, J. R., Roth, S., Ringold, J. C., Summers, R. W., Jarvinen, H. J., Sistonen, P., et al. (1998). Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science, 280(5366), 1086–1088.
Tascilar, M., Skinner, H. G., Rosty, C., Sohn, T., Wilentz, R. E., Offerhaus, G. J., et al. (2001). The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clinical Cancer Research, 7(12), 4115–4121.
Biankin, A. V., Morey, A. L., Lee, C. S., Kench, J. G., Biankin, S. A., Hook, H. C., et al. (2002). DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. Journal of Clinical Oncology, 20(23), 4531–4542.
Khorana, A. A., Hu, Y. C., Ryan, C. K., Komorowski, R. A., Hostetter, G., & Ahrendt, S. A. (2005). Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer. Journal of Gastrointestinal Surgery, 9(7), 903–911.
Schwarte-Waldhoff, I., Volpert, O. V., Bouck, N. P., Sipos, B., Hahn, S. A., Klein-Scory, S., et al. (2000). Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 97(17), 9624–9629.
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., et al. (2003). BRCA2 germline mutations in familial pancreatic carcinoma. Journal of the National Cancer Institute, 95(3), 214–221.
Murphy, K. M., Brune, K. A., Griffin, C., Sollenberger, J. E., Petersen, G. M., Bansal, R., et al. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Research, 62(13), 3789–3793.
Real, F. X., Malats, N., Lesca, G., Porta, M., Chopin, S., Lenoir, G. M., et al. (2002). Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer. Gut, 50(5), 653–657.
Tsiambas, E., Karameris, A., Dervenis, C., Lazaris, A. C., Giannakou, N., Gerontopoulos, K., et al. (2006). HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: A comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis. Journal of the Pancreas, 7(3), 283–294.
Safran, H., Steinhoff, M., Mangray, S., Rathore, R., King, T. C., Chai, L., et al. (2001). Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. American Journal of Clinical Oncology, 24(5), 496–499.
Talar-Wojnarowska, R., Gasiorowska, A., Smolarz, B., Romanowicz-Makowska, H., Strzelczyk, J., Janiak, A., et al. (2005). Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis. International Journal of Gastrointestinal Cancer, 35(1), 33–41.
Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Kunz, J., Beger, H. G., et al. (1993). Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Human Pathology, 24(10), 1127–1134.
Stoecklein, N. H., Luebke, A. M., Erbersdobler, A., Knoefel, W. T., Schraut, W., Verde, P. E., et al. (2004). Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. Journal of Clinical Oncology, 22(23), 4737–4745.
Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., & Beger, H. G. (1992). Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. Journal of Clinical Investigation, 90(4), 1352–1360.
Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Beger, H. G., & Korc, M. (1993). Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Research, 13(3), 565–569.
Durkin, A. J., Bloomston, P. M., Rosemurgy, A. S., Giarelli, N., Cojita, D., Yeatman, T. J., et al. (2003). Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. American Journal of Surgery, 186(5), 431–436.
Wang, Z., Zhang, Y., Banerjee, S., Li, Y., & Sarkar, F. H. (2006). Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer, 106(11), 2503–2513.
Wang, Z., Zhang, Y., Banerjee, S., Li, Y., & Sarkar, F. H. (2006). Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. International Journal of Cancer, 118(8), 1930–1936.
Buchler, P., Gazdhar, A., Schubert, M., Giese, N., Reber, H. A., Hines, O. J., et al. (2005). The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Annals of Surgery, 242(6), 791–800 discussion.
Taketo, M. M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). Journal of the National Cancer Institute, 90(20), 1529–1536.
Cheng, J. Q., Ruggeri, B., Klein, W. M., Sonoda, G., Altomare, D. A., Watson, D. K., et al. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proceedings of the National Academy of Sciences of the United States of America, 93(8), 3636–3641.
Fahy, B. N., Schlieman, M., Virudachalam, S., & Bold, R. J. (2003). AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. British Journal of Cancer, 89(2), 391–397.
Lebe, B., Sagol, O., Ulukus, C., Coker, A., Karademir, S., Astarcioglu, H., et al. (2004). The importance of cyclin D1 and Ki67 expression on the biological behavior of pancreatic adenocarcinomas. Pathology, Research and Practice, 200(5), 389–396.
Ebert, M. P., Hernberg, S., Fei, G., Sokolowski, A., Schulz, H. U., Lippert, H., et al. (2001). Induction and expression of cyclin D3 in human pancreatic cancer. Journal of Cancer Research and Clinical Oncology, 127(7), 449–454.
Ito, Y., Takeda, T., Wakasa, K., Tsujimoto, M., & Matsuura, N. (2001). Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Research, 21(2A), 1043–1048.
Andrianifahanana, M., Moniaux, N., Schmied, B. M., Ringel, J., Friess, H., Hollingsworth, M. A., et al. (2001). Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: A potential role of MUC4 as a tumor marker of diagnostic significance. Clinical Cancer Research, 7(12), 4033–4040.
Arumugam, T., Simeone, D. M., Van Golen, K., & Logsdon, C. D. (2005). S100P promotes pancreatic cancer growth, survival, and invasion. Clinical Cancer Research, 11(15), 5356–5364.
Morton, J. P., Mongeau, M. E., Klimstra, D. S., Morris, J. P., Lee, Y. C., Kawaguchi, Y., et al. (2007). Sonic hedgehog acts at multiple stages during pancreatic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 104(12), 5103–5108.
Thayer, S. P., di Magliano, M. P., Heiser, P. W., Nielsen, C. M., Roberts, D. J., Lauwers, G. Y., et al. (2003). Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature, 425(6960), 851–856.
Nakashima, H., Nakamura, M., Yamaguchi, H., Yamanaka, N., Akiyoshi, T., Koga, K., et al. (2006). Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. Cancer Research, 66(14), 7041–7049.
Gong, Y. L., Xu, G. M., Huang, W. D., & Chen, L. B. (2000). Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. Journal of Surgical Oncology, 73(2), 95–99.
Juuti, A., Lundin, J., Nordling, S., & Louhimo, J. (2006). Haglund C. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology, 71(1–2), 61–68.
Tobita, K., Kijima, H., Dowaki, S., Kashiwagi, H., Ohtani, Y., Oida, Y., et al. (2003). Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. International Journal of Molecular Medicine, 11(3), 305–309.
Ng, S. S., Tsao, M. S., Nicklee, T., & Hedley, D. W. (2002). Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Molecular Cancer Therapeutics, 1(10), 777–783.
Iannitti, D., Dipetrillo, T., Akerman, P., Barnett, J. M., Maia-Acuna, C., Cruff, D., et al. (2005). Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. American Journal of Clinical Oncology, 28(6), 570–575.
Dragovich, T., Huberman, M., Von Hoff, D. D., Rowinsky, E. K., Nadler, P., Wood, D., et al. (2007). Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemotherapy and Pharmacology, 60(2), 295–303.
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25(15), 1960–1966.
Wacker, B., Nagrani, T., Weinberg, J., Witt, K., Clark, G., & Cagnoni, P. J. (2007). Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clinical Cancer Research, 13(13), 3913–3921.
Buck, E., Eyzaguirre, A., Brown, E., Petti, F., McCormack, S., Haley, J. D., et al. (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular Cancer Therapeutics, 5(11), 2676–2684.
Buck, E., Eyzaguirre, A., Haley, J. D., Gibson, N. W., Cagnoni, P., & Iwata, K. K. (2006). Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Molecular Cancer Therapeutics, 5(8), 2051–2059.
El Rayes, B. F., Ali, S., Ali, I. F., Philip, P. A., Abbruzzese, J., & Sarkar, F. H. (2006). Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Research, 66(21), 10553–10559.
Kulke, M. H., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Meyerhardt, J. A., Zhu, A. X., et al. (2007). Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. Journal of Clinical Oncology, 25(30), 4787–4792.
Li, J., Kleeff, J., Giese, N., Buchler, M. W., Korc, M., & Friess, H. (2004). Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. International Journal of Oncology, 25(1), 203–210.
Knight, L. A., Di Nicolantonio, F., Whitehouse, P., Mercer, S., Sharma, S., Glaysher, S., et al. (2004). The in vitro effect of gefitinib (‘Iressa’) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer, 4, 83.
Rosetti, M., Tesei, A., Ulivi, P., Fabbri, F., Vannini, I., Brigliadori, G., et al. (2005). Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biology and Therapy, 4(10), 1089–1095.
Czito, B. G., Willett, C. G., Bendell, J. C., Morse, M. A., Tyler, D. S., Fernando, N. H., et al. (2006). Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. Journal of Clinical Oncology, 24(4), 656–662.
Maurel, J., Martin-Richard, M., Conill, C., Sanchez, M., Petriz, L., Gines, A., et al. (2006). Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer. International Journal of Radiation Oncology, Biology, Physics, 66(5), 1391–1398.
Carneiro, B. A., Brand, R. E., Fine, E., Knop, R. H., Khandekar, J. D., Uhlig, W., et al. (2007). Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma. Cancer Investigation, 25(5), 366–371.
Ignatiadis, M., Polyzos, A., Stathopoulos, G. P., Tselepatiotis, E., Christophylakis, C., Kalbakis, K., et al. (2006). A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabinepretreated patients with advanced/metastatic pancreatic cancer. Oncology, 71(3–4), 159–163.
Bruns, C. J., Solorzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R., Fan, D., et al. (2000). Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Research, 60(11), 2926–2935.
Baker, C. H., Solorzano, C. C., & Fidler, I. J. (2002). Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Research, 62(7), 1996–2003.
Solorzano, C. C., Baker, C. H., Tsan, R., Traxler, P., Cohen, P., Buchdunger, E., et al. (2001). Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clinical Cancer Research, 7(8), 2563–2572.
Safran, H., Iannitti, D., Miner, T., Demel, K., Yoo, D., Joseph, P., et al. (2006). GW572016, gemcitabine and GW572016, gemcitabine, oxaliplatin, a two-stage, phase I study for advanced pancreaticobiliary cancer. Journal of Clinical Oncology (Meeting Abstracts), 24(18_suppl), 4002.
Buchler, P., Reber, H. A., Buchler, M. C., Roth, M. A., Buchler, M. W., Friess, H., et al. (2001). Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). Journal of Gastrointestinal Surgery, 5(2), 139–146.
Kimura, K., Sawada, T., Komatsu, M., Inoue, M., Muguruma, K., Nishihara, T., et al. (2006). Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clinical Cancer Research, 12(16), 4925–4932.
Larbouret, C., Robert, B., Navarro-Teulon, I., Thezenas, S., Ladjemi, M. Z., Morisseau, S., et al. (2007). In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clinical Cancer Research, 13(11), 3356–3362.
Saeki, H., Yanoma, S., Takemiya, S., Sugimasa, Y., Akaike, M., Yukawa, N., et al. (2007). Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Oncology Reports, 18(2), 433–439.
Safran, H., Iannitti, D., Ramanathan, R., Schwartz, J. D., Steinhoff, M., Nauman, C., et al. (2004). Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investigation, 22(5), 706–712.
Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R., McConkey, D. J., et al. (2000). Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clinical Cancer Research, 6(5), 1936–1948.
Overholser, J. P., Prewett, M. C., Hooper, A. T., Waksal, H. W., & Hicklin, D. J. (2000). Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer, 89(1), 74–82.
Buchsbaum, D. J., Bonner, J. A., Grizzle, W. E., Stackhouse, M. A., Carpenter, M., Hicklin, D. J., et al. (2002). Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. International Journal of Radiation Oncology, Biology, Physics, 54(4), 1180–1193.
Huang, Z. Q., Buchsbaum, D. J., Raisch, K. P., Bonner, J. A., Bland, K. I., & Vickers, S. M. (2003). Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. Journal of Surgical Research, 111(2), 274–283.
Arnoletti, J. P., Buchsbaum, D. J., Huang, Z. Q., Hawkins, A. E., Khazaeli, M. B., Kraus, M. H., et al. (2004). Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. Journal of Gastrointestinal Surgery, 8(8), 960–969.
Sclabas, G. M., Fujioka, S., Schmidt, C., Fan, Z., Evans, D. B., & Chiao, P. J. (2003). Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the antiepidermal growth factor antibody IMC-C225. Journal of Gastrointestinal Surgery, 7(1), 37–43.
Tonra, J. R., Deevi, D. S., Corcoran, E., Li, H., Wang, S., Carrick, F. E., et al. (2006). Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clinical Cancer Research, 12(7 Pt 1), 2197–2207.
Xiong, H. Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R. A., Deutsch, J., et al. (2004). Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. Journal of Clinical Oncology, 22(13), 2610–2616.
Philip, P. A., Benedetti, J., Fenoglio-Preiser, C., Zalupski, M., Lenz, H., O’Reilly, E., et al. (2007). Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Journal of Clinical Oncology (Meeting Abstracts), 25(18_suppl), LBA4509.
Burtness, B. A., Powell, M., Berlin, J., Liles, D., Chapman, A., Mitchell, E., et al. (2007). Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r): Eastern Cooperative Oncology. Journal of Clinical Oncology (Meeting Abstracts), 25(18_suppl), 4519.
Graeven, U., Kremer, B., Sudhoff, T., Killing, B., Rojo, F., Weber, D., et al. (2006). Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. British Journal of Cancer, 94(9), 1293–1299.
Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., Davis, C. G., & Jakobovits, A. (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research, 59(6), 1236–1243.
Yang, X. D., Jia, X. C., Corvalan, J. R., Wang, P., & Davis, C. G. (2001). Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Critical Reviews in Oncology/Hematology, 38(1), 17–23.
Egawa, S., Tsutsumi, M., Konishi, Y., Kobari, M., Matsuno, S., Nagasaki, K., et al. (1995). The role of angiogenesis in the tumor growth of Syrian hamster pancreatic cancer cell line HPD-NR. Gastroenterology, 108(5), 1526–1533.
Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Buchler, M. W., et al. (1997). Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clinical Cancer Research, 3(8), 1309–1316.
Ikeda, N., Adachi, M., Taki, T., Huang, C., Hashida, H., Takabayashi, A., et al. (1999). Prognostic significance of angiogenesis in human pancreatic cancer. British Journal of Cancer, 79(9–10), 1553–1563.
Buchler, P., Reber, H. A., Buchler, M. W., Friess, H., & Hines, O. J. (2002). VEGF-RII influences the prognosis of pancreatic cancer. Annals of Surgery, 236(6), 738–749.
Fujimoto, K., Hosotani, R., Wada, M., Lee, J. U., Koshiba, T., Miyamoto, Y., et al. (1998). Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. European Journal of Cancer, 34(9), 1439–1447.
Bruns, C. J., Shrader, M., Harbison, M. T., Portera, C., Solorzano, C. C., Jauch, K. W., et al. (2002). Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. International Journal of Cancer, 102(2), 101–108.
Hotz, H. G., Reber, H. A., Hotz, B., Sanghavi, P. C., Yu, T., Foitzik, T., et al. (2001). Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. Journal of Gastrointestinal Surgery, 5(2), 131–138.
Kindler, H. L., Friberg, G., Singh, D. A., Locker, G., Nattam, S., Kozloff, M., et al. (2005). Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology, 23(31), 8033–8040.
Kim, G. P., Oberg, A. L., Foster, N. R., Jaslowski, A., Flynn, P. J., Campbell, D., et al. (2007). Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology (Meeting Abstracts), 25(18_suppl), 4553.
Kindler, H. L., Niedzwiecki, D., Hollis, D., Oraefo, E., Schrag, D., Hurwitz, H., et al. (2007). A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB. Journal of Clinical Oncology (Meeting Abstracts), 25(18_suppl), 4508.
Crane, C. H., Ellis, L. M., Abbruzzese, J. L., Amos, C., Xiong, H. Q., Ho, L., et al. (2006). Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. Journal of Clinical Oncology, 24(7), 1145–1151.
Solorzano, C. C., Baker, C. H., Bruns, C. J., Killion, J. J., Ellis, L. M., Wood, J., et al. (2001). Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm, 16(5), 359–370.
Kuo, T., Fitzgerald, A., Kaiser, H., Sikic, B. I., & Fisher, G. A. (2006). A phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology (Meeting Abstracts), 24(18_suppl), 4122.
Bianco, C., Giovannetti, E., Ciardiello, F., Mey, V., Nannizzi, S., Tortora, G., et al. (2006). Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clinical Cancer Research, 12(23), 7099–7107.
Conrad, C., Ischenko, I., Kohl, G., Wiegand, U., Guba, M., Yezhelyev, M., et al. (2007). Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs, 18(5), 569–579.
Siu, L. L., Awada, A., Takimoto, C. H., Piccart, M., Schwartz, B., Giannaris, T., et al. (2006). Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clinical Cancer Research, 12(1), 144–151.
Rosemurgy, A., Harris, J., Langleben, A., Casper, E., Goode, S., & Rasmussen, H. (1999). Marimastat in patients with advanced pancreatic cancer: a dose-finding study. American Journal of Clinical Oncology, 22(3), 247–252.
Bramhall, S. R., Rosemurgy, A., Brown, P. D., Bowry, C., & Buckels, J. A. (2001). Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. Journal of Clinical Oncology, 19(15), 3447–3455.
Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., & Buckels, J. A. (2002). A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. British Journal of Cancer, 87(2), 161–167.
Kilian, M., Gregor, J. I., Heukamp, I., Hanel, M., Ahlgrimm, M., Schimke, I., et al. (2006). Matrix metalloproteinase inhibitor RO 28–2653 decreases liver metastasis by reduction of MMP-2 and MMP-9 concentration in BOP-induced ductal pancreatic cancer in Syrian Hamsters: inhibition of matrix metalloproteinases in pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids, 75(6), 429–434.
Moore, M. J., Hamm, J., Dancey, J., Eisenberg, P. D., Dagenais, M., Fields, A., et al. (2003). Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 21(17), 3296–3302.
Cohen, S. J., Ho, L., Ranganathan, S., Abbruzzese, J. L., Alpaugh, R. K., Beard, M., et al. (2003). Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Journal of Clinical Oncology, 21(7), 1301–1306.
Macdonald, J. S., McCoy, S., Whitehead, R. P., Iqbal, S., Wade III, J. L., Giguere, J. K., et al. (2005). A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Investigational New Drugs, 23(5), 485–487.
Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W. L., Szawlowski, A., et al. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. Journal of Clinical Oncology, 22(8), 1430–1438.
Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Lipari, P., et al. (1998). Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Research, 58(21), 4947–4956.
Nielsen, L. L., Shi, B., Hajian, G., Yaremko, B., Lipari, P., Ferrari, E., et al. (1999). Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Research, 59(23), 5896–5901.
Eskens, F. A., Awada, A., Cutler, D. L., de Jonge, M. J., Luyten, G. P., Faber, M. N., et al. (2001). Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. Journal of Clinical Oncology, 19(4), 1167–1175.
Awada, A., Eskens, F. A., Piccart, M., Cutler, D. L., van der Gaast, A., Bleiberg, H., et al. (2002). Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. European Journal of Cancer, 38(17), 2272–2278.
Raut, C. P., Nawrocki, S., Lashinger, L. M., Davis, D. W., Khanbolooki, S., Xiong, H., et al. (2004). Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biology and Therapy, 3(12), 1217–1224.
Wei, D., Wang, L., He, Y., Xiong, H. Q., Abbruzzese, J. L., & Xie, K. (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Research, 64(6), 2030–2038.
Fife, R. S., Stott, B., & Carr, R. E. (2004). Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. Cancer Biology and Therapy, 3(2), 228–232.
Blanquicett, C., Saif, M. W., Buchsbaum, D. J., Eloubeidi, M., Vickers, S. M., Chhieng, D. C., et al. (2005). Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clinical Cancer Research, 11(24 Pt 1), 8773–8781.
El Rayes, B. F., Ali, S., Sarkar, F. H., & Philip, P. A. (2004). Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Molecular Cancer Therapeutics, 3(11), 1421–1426.
Ali, S., El Rayes, B. F., Sarkar, F. H., & Philip, P. A. (2005). Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Molecular Cancer Therapeutics, 4(12), 1943–1951.
Lev-Ari, S., Zinger, H., Kazanov, D., Yona, D., Ben Yosef, R., Starr, A., et al. (2005). Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomedicine & Pharmacotherapy, 59(Suppl 2), S276–S280.
Milella, M., Gelibter, A., Di Cosimo, S., Bria, E., Ruggeri, E. M., Carlini, P., et al. (2004). Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer, 101(1), 133–138.
Kerr, S., Campbell, C., Legore, K., Witters, L., Harvey, H., & Lipton, A. (2005). Phase II trial of gemcitabine and irinotecan plus celecoxib in advanced adenocarcinoma of the pancreas. Journal of Clinical Oncology (Meeting Abstracts), 23(16_suppl), 4155.
El Rayes, B. F., Zalupski, M. M., Shields, A. F., Ferris, A. M., Vaishampayan, U., Heilbrun, L. K., et al. (2005). A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Investigational New Drugs, 23(6), 583–590.
Ferrari, V., Valcamonico, F., Amoroso, V., Simoncini, E., Vassalli, L., Marpicati, P., et al. (2006). Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemotherapy and Pharmacology, 57(2), 185–190.
Jimeno, A., Amador, M. L., Kulesza, P., Wang, X., Rubio-Viqueira, B., Zhang, X., et al. (2006). Assessment of celecoxib pharmacodynamics in pancreatic cancer. Molecular Cancer Therapeutics, 5(12), 3240–3247.
Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., & Beasley, R. (2006). Risk of cardiovascular events and celecoxib: A systematic review and meta-analysis. Journal of the Royal Society of Medicine, 99(3), 132–140.
White, W. B., West, C. R., Borer, J. S., Gorelick, P. B., Lavange, L., Pan, S. X., et al. (2007). Risk of cardiovascular events in patients receiving celecoxib: A meta-analysis of randomized clinical trials. American Journal of Cardiology, 99(1), 91–98.
Chen, L. C., & Ashcroft, D. M. (2007). Risk of myocardial infarction associated with selective COX-2 inhibitors: Meta-analysis of randomised controlled trials. Pharmacoepidemiology and Drug Safety, 16(7), 762–772.
Kearney, P. M., Baigent, C., Godwin, J., Halls, H., Emberson, J. R., & Patrono, C. (2006). Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ, 332(7553), 1302–1308.
Chen, J., Ouyang, Z. G., Zhang, S. H., & Zhen, Y. S. (2007). Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth. Oncology Reports, 17(6), 1445–1451.
Dhillon, N., Wolff, R. A., Abbruzzese, J. L., Hong, D. S., Camacho, L. H., Li, L., et al. (2006). Phase II clinical trial of curcumin in patients with advanced pancreatic cancer. Journal of Clinical Oncology (Meeting Abstracts), 24(18_suppl), 14151.
Kunnumakkara, A. B., Guha, S., Krishnan, S., Diagaradjane, P., Gelovani, J., & Aggarwal, B. B. (2007). Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB regulated gene products. Cancer Research, 67(8), 3853–3861.
Banerjee, S., Zhang, Y., Ali, S., Bhuiyan, M., Wang, Z., Chiao, P. J., et al. (2005). Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Research, 65(19), 9064–9072.
Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O., & Sarkar, F. H. (2005). Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Research, 65(15), 6934–6942.
Sclabas, G. M., Uwagawa, T., Schmidt, C., Hess, K. R., Evans, D. B., Abbruzzese, J. L., et al. (2005). Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer, 103(12), 2485–2490.
Yip-Schneider, M. T., Nakshatri, H., Sweeney, C. J., Marshall, M. S., Wiebke, E. A., & Schmidt, C. M. (2005). Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics, 4(4), 587–594.
Shiah, H. S., Gao, W., Baker, D. C., & Cheng, Y. C. (2006). Inhibition of cell growth and nuclear factor-kappaB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503. Molecular Cancer Therapeutics, 5(10), 2484–2493.
Shah, S. A., Potter, M. W., McDade, T. P., Ricciardi, R., Perugini, R. A., Elliott, P. J., et al. (2001). 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. Journal of Cellular Biochemistry, 82(1), 110–122.
Bold, R. J., Virudachalam, S., & McConkey, D. J. (2001). Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. Journal of Surgical Research, 100(1), 11–17.
Nawrocki, S. T., Bruns, C. J., Harbison, M. T., Bold, R. J., Gotsch, B. S., Abbruzzese, J. L., et al. (2002). Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Molecular Cancer Therapeutics, 1(14), 1243–1253.
Bai, J., Demirjian, A., Sui, J., Marasco, W., & Callery, M. P. (2006). Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 348(4), 1245–1253.
Alberts, S. R., Foster, N. R., Morton, R. F., Kugler, J., Schaefer, P., Wiesenfeld, M., et al. (2005). PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) randomized phase II study. Annals of Oncology, 16(10), 1654–1661.
Lutz, M. P., Esser, I. B., Flossmann-Kast, B. B., Vogelmann, R., Luhrs, H., Friess, H., et al. (1998). Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochemical and Biophysical Research Communications, 243(2), 503–508.
Ito, H., Gardner-Thorpe, J., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2003). Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery, 134(2), 221–226.
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004). Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clinical Cancer Research, 10(7), 2307–2318.
Trevino, J. G., Summy, J. M., Lesslie, D. P., Parikh, N. U., Hong, D. S., Lee, F. Y., et al. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. American Journal of Pathology, 168(3), 962–972.
Hennequin, L. F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T. P., et al. (2006). N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. Journal of Medicinal Chemistry, 49(22), 6465–6488.
Baker, C. H., Trevino, J. G., Summy, J. M., Zhang, F., Caron, A., Nesbit, M., et al. (2006). Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. International Journal of Oncology, 29(1), 125–138.
Yezhelyev, M. V., Koehl, G., Guba, M., Brabletz, T., Jauch, K. W., Ryan, A., et al. (2004). Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clinical Cancer Research, 10(23), 8028–8036.
Hollingsworth, M. A., Strawhecker, J. M., Caffrey, T. C., & Mack, D. R. (1994). Expression of MUC1, MUC2, MUC3 and MUC4 mucin mRNAs in human pancreatic and intestinal tumor cell lines. International Journal of Cancer, 57(2), 198–203.
Swartz, M. J., Batra, S. K., Varshney, G. C., Hollingsworth, M. A., Yeo, C. J., Cameron, J. L., et al. (2002). MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. American Journal of Clinical Pathology, 117(5), 791–796.
Chaturvedi, P., Singh, A. P., Moniaux, N., Senapati, S., Chakraborty, S., Meza, J. L., et al. (2007). MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Molecular Cancer Research, 5(4), 309–320.
Saitou, M., Goto, M., Horinouchi, M., Tamada, S., Nagata, K., Hamada, T., et al. (2005). MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. Journal of Clinical Pathology, 58(8), 845–852.
Singh, A. P., Moniaux, N., Chauhan, S. C., Meza, J. L., & Batra, S. K. (2004). Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Research, 64(2), 622–630.
Furuyama, K., Doi, R., Mori, T., Toyoda, E., Ito, D., Kami, K., et al. (2006). Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World Journal of Surgery, 30(2), 219–226.
Sawai, H., Okada, Y., Funahashi, H., Matsuo, Y., Takahashi, H., Takeyama, H., et al. (2005). Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation. Molecular Cancer, 4, 37.
Huang, Y. T., Lee, L. T., Lee, P. P., Lin, Y. S., & Lee, M. T. (2005). Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability. Anticancer Research, 25(3B), 2017–2025.
Duxbury, M. S., Ito, H., Benoit, E., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2003). RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochemical and Biophysical Research Communications, 311(3), 786–792.
Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2004). Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery, 135(5), 555–562.
Grewe, M., Gansauge, F., Schmid, R. M., Adler, G., & Seufferlein, T. (1999). Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Research, 59(15), 3581–3587.
Shah, S. A., Potter, M. W., Ricciardi, R., Perugini, R. A., & Callery, M. P. (2001). FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. Journal of Surgical Research, 97(2), 123–130.
Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., & Reddy, S. A. (2005). The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochemical and Biophysical Research Communications, 331(1), 295–302.
Ito, D., Fujimoto, K., Mori, T., Kami, K., Koizumi, M., Toyoda, E., et al. (2006). In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. International Journal of Cancer, 118(9), 2337–2343.
Kobayashi, S., Kishimoto, T., Kamata, S., Otsuka, M., Miyazaki, M., & Ishikura, H. (2007). Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Science, 98(5), 726–733.
Ozawa, F., Friess, H., Kleeff, J., Xu, Z. W., Zimmermann, A., Sheikh, M. S., et al. (2001). Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Letters, 163(1), 71–81.
Matsuzaki, H., Schmied, B. M., Ulrich, A., Standop, J., Schneider, M. B., Batra, S. K., et al. (2001). Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clinical Cancer Research, 7(2), 407–414.
Xu, Z. W., Kleeff, J., Friess, H., Buchler, M. W., & Solioz, M. (2003). Synergistic cytotoxic effect of TRAIL and gemcitabine in pancreatic cancer cells. Anticancer Research, 23(1A), 251–258.
Mori, T., Doi, R., Toyoda, E., Koizumi, M., Ito, D., Kami, K., et al. (2005). Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Surgery, 138(1), 71–77.
Wang, P., Zhang, J., Bellail, A., Jiang, W., Hugh, J., Kneteman, N. M., et al. (2007). Inhibition of RIP and c- FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal, 19(11), 2237–2246.
Vogler, M., Durr, K., Jovanovic, M., Debatin, K. M., & Fulda, S. (2007). Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells. Oncogene, 26(2), 248–257.
Khanbolooki, S., Nawrocki, S. T., Arumugam, T., Andtbacka, R., Pino, M. S., Kurzrock, R., et al. (2006). Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Molecular Cancer Therapeutics, 5(9), 2251–2260.
Braeuer, S. J., Buneker, C., Mohr, A., & Zwacka, R. M. (2006). Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Molecular Cancer Research, 4(10), 715–728.
Koschny, R., Ganten, T. M., Sykora, J., Haas, T. L., Sprick, M. R., Kolb, A., et al. (2007). TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology, 45(3), 649–658.
Hylander, B. L., Pitoniak, R., Penetrante, R. B., Gibbs, J. F., Oktay, D., Cheng, J., et al. (2005). The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. Journal of Translational Medicine, 3(1), 22.
Katz, M. H., Spivack, D. E., Takimoto, S., Fang, B., Burton, D. W., Moossa, A. R., et al. (2003). Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosisinducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter. Annals of Surgical Oncology, 10(7), 762–772.
Jacob, D., Davis, J., Zhu, H., Zhang, L., Teraishi, F., Wu, S., et al. (2004). Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clinical Cancer Research, 10(10), 3535–3541.
Nozawa, F., Itami, A., Saruc, M., Kim, M., Standop, J., Picha, K. S., et al. (2004). The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) and Genistein is effective in inhibiting pancreatic cancer growth. Pancreas, 29(1), 45–52.
Fulda, S., & Debatin, K. M. (2004). Sensitization for tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis by the chemopreventive agent resveratrol. Cancer Research, 64(1), 337–346.
Retzer-Lidl, M., Schmid, R. M., & Schneider, G. (2007). Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. International Journal of Cancer, 121(1), 66–75.
Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., et al. (2006). TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene, 25(56), 7434–7439.
Wack, S., Rejiba, S., Parmentier, C., Aprahamian, M., & Hajri, A. (2008). Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Molecular Therapy, 16(2), 252–260.
Gysin, S., Lee, S. H., Dean, N. M., & McMahon, M. (2005). Pharmacologic inhibition of RAF→MEK→ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Cancer Research, 65(11), 4870–4880.
Lorusso, P. M., Adjei, A. A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D. Y., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. Journal of Clinical Oncology, 23(23), 5281–5293.
Rinehart, J., Adjei, A. A., Lorusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., et al. (2004). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. Journal of Clinical Oncology, 22(22), 4456–4462.
Moore, P. S., Barbi, S., Donadelli, M., Costanzo, C., Bassi, C., Palmieri, M., et al. (2004). Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta, 1693(3), 167–176.
Donadelli, M., Costanzo, C., Faggioli, L., Scupoli, M. T., Moore, P. S., Bassi, C., et al. (2003). Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Molecular Carcinogenesis, 38(2), 59–69.
Ryu, J. K., Lee, W. J., Lee, K. H., Hwang, J. H., Kim, Y. T., Yoon, Y. B., et al. (2006). SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Letters, 237(1), 143–154.
Sato, N., Ohta, T., Kitagawa, H., Kayahara, M., Ninomiya, I., Fushida, S., et al. (2004). FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. International Journal of Oncology, 24(3), 679–685.
Piacentini, P., Donadelli, M., Costanzo, C., Moore, P. S., Palmieri, M., & Scarpa, A. (2006). Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Archiv, 448(6), 797–804.
Donadelli, M., Costanzo, C., Beghelli, S., Scupoli, M. T., Dandrea, M., Bonora, A., et al. (2007). Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochimica Et Biophysica Acta, 1773(7), 1095–1106.
Arnold, N. B., Arkus, N., Gunn, J., & Korc, M. (2007). The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clinical Cancer Research, 13(1), 18–26.
Kumagai, T., Wakimoto, N., Yin, D., Gery, S., Kawamata, N., Takai, N., et al. (2007). Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. International Journal of Cancer, 121(3), 656–665.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Strimpakos, A., Saif, M.W. & Syrigos, K.N. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 27, 495–522 (2008). https://doi.org/10.1007/s10555-008-9134-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-008-9134-y